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&p.1:Abstract. In this study the potential of intraperitoneal
(i.p.) and intravenous (i.v.) administration of chimeric
iodine-131-labelled MOv18 IgG for radioimmunothera-
py was determined. The dosimetry associated with both
routes of administration of cMOv18 IgG was studied in
patients. Eight patients suspected of having ovarian car-
cinoma received 150 MBq 131I-cMOv18 IgG i.p. Blood
and urine were collected and serial gamma camera imag-
es were acquired. Another group of four patients re-
ceived 7.5 MBq 131I-cMOv18 IgG i.v. For all patients,
tissue biopsies were obtained at surgery. Activity in the
blood after i.p. administration was described by a bi-ex-
ponential curve with a mean uptake and elimination
half-life of 6.9±3.2 h and 160±45 h, respectively. For i.v.
infusion the mean half-life for the elimination phase was
103±12 h. Cumulative excretion in the urine was
17%±3% ID and 21%±7% ID in 96 h for i.p. and i.v. ad-
ministration, respectively. Scintigraphic images after i.p.
administration showed accumulation in ovarian cancer
lesions, while all other tissues showed decreasing activi-
ty with time. Tumour uptake determined in the ovarian
cancer tissue specimens ranged from 3.4% to 12.3%
ID/kg for i.p. administration and from 3.6% to 5.4%
ID/kg for i.v. administration. Dosimetric analysis of
the data indicated that 1.7–4.3 mGy/MBq and
1.7–2.2 mGy/MBq can be guided to solid or ascites cells
after i.p. and i.v. administration, respectively. Assuming
that an absorbed dose to the bone marrow of 2 Gy will
be dose limiting, a total activity of 4.1 GBq 131I-
cMOv18 IgG can be administered safely via the i.p.
route and 3.5 GBq via the i.v. route. At this maximal tol-
erated dose, a maximum absorbed dose to 1-g tumours
in the peritoneal cavity of 18 and 8 Gy can be reached
after i.p. and i.v. administration, respectively. For the i.p.
route of administration, dose estimates for the tumour
are even higher when the electron dose of the peritoneal
activity is also taken into account: total doses to the tu-
mour of 30 Gy and 22 Gy will be absorbed at the tumour
surface and at 0.2 mm depth, respectively. In conclusion,
therapeutic tumour doses can be achieved with 131I-
cMOv18 IgG in patients with intraperitoneal ovarian
cancer lesions with no normal organ toxicity. The i.p.
route of administration seems to be preferable to i.v. ad-
ministration.
&kwd:Key words: Internal radiation dosimetry – Radionuclides
– Intraperitoneal – Radioimmunotherapy – Ovarian can-
cer
Eur J Nucl Med (1998) 25:1552–1561
Introduction
Radioimmunoscintigraphy (RIS) studies in ovarian can-
cer patients have demonstrated preferential tumour lo-
calisation of several radiolabelled anti-tumour monoclo-
nal antibodies (MAbs) in vivo. In RIS with iodine-131
labelled murine MOv18 IgG an overall sensitivity of
84% was achieved [1]. Also the chimeric form of
MOv18 (cMOv18) has been studied extensively in ex-
perimental models and in ovarian cancer patients [2–4].
Several studies have focussed on guiding therapeutic
doses of radioactivity to ovarian cancer tumours with an-
ti-tumour MAbs [5, 6]. For therapeutic purposes radiola-
belled MAbs can be administered either systemically or
locoregionally. After intravenous (i.v.) administration all
disseminated tumour lesions can be reached [7, 8], while
locoregional administration may be favourable in the
treatment of diseases which are known to spread locally.
Ovarian cancer is a malignancy whose spread initially is
confined to the peritoneal cavity [1]. In the majority of
ovarian cancer radioimmunotherapy (RIT) studies, the
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radiolabeled antibody has been administered intraperito-
neally (i.p.) [5]. Dosimetric analysis of biodistribution
studies in mice with ovarian cancer xenografts indicated
that higher radiation doses were guided to solid tumour
deposits after i.p. administration [9]. Several studies in
ovarian carcinoma patients indicated that therapeutic re-
sponses can be achieved in patients with small tumour
deposits after i.p. administration [5, 6]. Intraperitoneal
administration of radiolabelled MAbs may reduce the
toxicity to the dose-limiting organ (e.g. bone marrow),
allowing the administration of higher doses [1, 9].
The aim of the present study was to investigate the
dosimetry associated with the i.p. and i.v. administration
of radioiodinated cMOv18 IgG in ovarian cancer pa-
tients. Because the potential for therapy was a major
consideration, the relation between tumour and red mar-
row dose was analysed for both the i.p. and the i.v. route
of administration [10, 11]. Special emphasis was given
to estimation of the dose to small tumour lesions, be-
cause small tumours are considered to be an optimal tar-
get for RIT [12, 13].
Materials and methods
Patients. &p.2:Patients suspected of having ovarian cancer who were
scheduled to undergo exploratory laparotomy were entered in the
study. Patients had to be over the age of 18 years and had to have
a life expectancy of at least 3 months. The study was conducted
with the approval of the Internal Review Board of the University
Hospital Nijmegen or the University Hospital Vrije Universiteit
Amsterdam, The Netherlands. Written informed consent was ob-
tained from each patient prior to study entry.
Study design. &p.2:Access to the i.p. cavity was obtained by insertion
of a Verres needle under local anaesthesia. If present, the ascites
was withdrawn from the peritoneal cavity prior to infusion. Pa-
tients received an i.p. infusion of approximately 1.5 l of normal
saline (37°C) followed by a single i.p. infusion of 150 MBq 131I-
cMOv18 IgG in 50 ml of saline. Protein doses of 30–80 mg were
administered. The thyroid was blocked with 100 mg potassium io-
dide two times a day and potassium perchlorate 200 mg four times
a day orally starting 4 h before the infusion and continuing for 2
weeks. Patient characteristics are summarized in Table 1. For
comparison, another group of patients received 7.5 MBq 131I-
cMOv18 IgG by i.v. infusion during 2 h [14].
Blood samples were collected just prior to the antibody admin-
istration and at various time points until surgery. The biological
half-life of disappearance from the blood was calculated using
non-linear least square regression analysis. To determine renal ex-
cretion, urine was collected in 24-h fractions. All activity data
were corrected for physical decay.
After i.p. administration anterior and posterior total body im-
ages were obtained at five different time points. Images were ob-
tained with a dual-headed gamma camera (Type MultiSpect2, Sie-
mens Inc., Hoffman Estates, Ill., USA) equipped with high-energy
collimators.
Surgery was performed 6–8 days post infusion in all patients.
The tumour status was carefully mapped and examined by histo-
logical techniques. Ascites and peritoneal washings were collect-
ed. Suspected tissues were either removed or biopsied. If feasible,
tissue samples of muscle, skin and normal omentum were ob-
tained. All tissues removed at surgery were weighed and the
Table 1. Patient characteristics &/tbl.c:&tbl.b:
Patient MAb Age FIGO Histologyb Diff.
no. (mg) (yr) stagea grade
Intraperitoneal administration
1 15 64 NA Serous cystadenoma NA
2 15 46 IIIa Malignant mixed III
Müllerian tumour
3 15 68 Ic Corpus carcinoma II
4 30 37 NA Benign teratoma NA
5 30 18 NA Non-Hodgkin NA
lymphoma
6 30 41 NA Serous cystadenoma NA
9 50 45 IIIc Serous III
cystadenocarcinoma
10 80 78 IIc Endometrioid III
adenocarcinoma
Intravenous administration
8 30 53 IIIc Clear cell (coeloma) II
11 30 45 NA Benign –
12 50 43 IIIc Serous III
15 75 55 IIIc Serous III
NA, not applicable
a Stage at first diagnosis according to the Féderation Internationale de Gynaecology et
Obstetrique
b Pathological classification of epithelial ovarian carcinoma at first diagnosis: grade I,
well-differentiated carcinoma; grade II, moderately differentiated carcinoma; grade III,
poorly differentiated carcinoma &/tbl.b:
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amount of radioactivity of 131I was measured in a well-type gam-
ma counter. The total activity in the whole resected tumour was
measured, as well as activity in selected small tumour deposits.
Dosimetric analysis. &p.2:Methods consistent with those recommended
by the MIRD Committee of the Society of Nuclear Medicine were
used to determine the absorbed dose to the normal organs, tumour
and the whole body [15]. The absorbed doses in organs were ex-
pressed as mGy/MBq.
For quantification of activity from gamma camera images after
i.p. administration, the conjugate view counting technique was
used [16]. A correction for differences in attenuation between ab-
domen, thorax and extremities was performed based on transmis-
sion scans. After correction for physical decay, the retention of ac-
tivity in the abdomen, peritoneal cavity or total body region of in-
terest (ROI) was expressed as a percentage of the injected dose (%
ID), setting the initial total body scintigraphic recording as 100%
injected dose.
It was assumed that on the first image (1 h post infusion), all
activity infused via the i.p. route of administration was localised
in the abdomen. During the first 24 h post infusion (p.i.) the intra-
abdominal organs were surrounded by activity. During this time
virtually no radioactivity had entered the circulation. The count
rate data from the ROIs of the abdominal organs, such as liver,
spleen and kidney, during this time do not reflect radioactivity up-
take, but rather represent the radioactivity surrounding these or-
gans. At later time points no accumulation of radioactivity in the
abdominal organs was observed, and it was assumed that the ra-
dioactivity in the abdominal organs represented blood perfusion
only.
The activity in the peritoneal cavity was estimated, assuming
that the activity in the abdomen ROI was partly the result of blood
perfusion of the organs in the abdominal region. The fractional
blood volume (FBV) in the organs situated in the ROI of the abdo-
men was estimated from data published in ICRP 23 and ICRP 53
[17, 18], (Table 2). The blood content of intra-abdominal organs
was assumed to be 150 ml/kg tissue in cases when published data
were not available. The sum of the FBVs for the abdominal organs
was 0.1835 (Table 2). Therefore 20% of the total blood activity
was assumed to be present in the abdominal organs. Assuming
that no activity was present in the urinary bladder at the time of
imaging, the retention of radioactivity in the peritoneal cavity was
calculated for each time point according the formula:
Retention in peritoneal cavity (%ID)
= (1)
%ID in the ROI of the abdomen –0.2× total blood activity 
–%ID in the ROI of the tumour
For each patient, the absorbed dose to the target organs, due to
peritoneal cavity activity, was calculated as the product of the res-
idence time (area under the time-activity curve of the peritoneal
cavity) and the photon S-values for 131I in the peritoneal cavity as
calculated by Watson et al. [19].
The absorbed doses to the target organs due to activity in the
total body minus the peritoneal cavity was calculated using the
MIRDOSE3 program [20], selecting the anthropomorphic phan-
tom for the “adult female”. The urinary bladder, the red marrow,
the ovarian tumours and the “rest of the body” were considered as
source organs following i.p. infusion of the MAb. The residence
time of the “rest of the body” was calculated as the residence time
of the total body minus the sum of the residence times of the peri-
toneal cavity, the red marrow and the ovarian tumours. A uniform
distribution of the activity in the “rest of the body” was assumed.
The residence time for the urinary bladder was calculated from
the activity excreted in the urine up to 144 h p.i., using a voiding
interval of 4 h.
For each target organ the sum of the MIRDOSE3 doses and
the dose due to the activity in the peritoneal cavity was calculated.
For the i.v. route of administration, the urinary bladder, the red
marrow and the “rest of the body” were considered as source or-
Table 2. Fractional blood volume for 
organs and tissue inside the abdominal ROI &/tbl.c:&tbl.b: Weighta Blood contentb Fractional
(g) (ml/kg) blood volumeb
Liver 1800 139 0.0481
Spleen 180 500 0.0173
Gallbladder wall 11 150 0.00032
Stomach wall 150 150 0.0043
Small intestine wall 640 150 0.0185
Large intestine wall 370 150 0.0107
Kidneys 310 226 0.0135
Urinary bladder wall 45 150 0.0013
Uterus 80 150 0.0023
Ovaries 11 150 0.00032
Musclec) 5600 – 0.0269
Skinc, d) 470 – 0.018
Trabecular bonec) 220 25 0.00158
Cortical bonec) 497 28 0.00268
Marrowc) 725 127 0.0177
Total fractional blood volume 0.1835
a Data derived from ICRP 23, Table 105 [17]
b Data derived from ICRP 53, Table A.2 [18]
c For muscle, skin, bone and red marrow a proportionate part of the total organ weight and
organ blood content is estimated to be present in the abdomen ROI
d It was assumed that the body surface of the abdominal region was approximately 18% of
the total body surface and that the total skin receives 10% of the heart minute volume &/tbl.b:
gans. The retention in the total body at 24 and 96 h p.i. was calcu-
lated as the difference between the injected activity and the cumu-
lative urinary excretion at those time points. The absorbed organ
doses were calculated from the residence times of the source or-
gans pooled for all patients, using the MIRDOSE3 program [20].
Red marrow dosimetry. &p.2:Since no activity was visualised in the
skeleton and/or the bone marrow, it was assumed that blood activ-
ity was the primary contributor to the absorbed dose in the red
marrow. It was also assumed that the marrow activity concentra-
tion was 25% of the blood activity concentration [21]. For an
adult female the whole blood and red marrow were assumed to
weigh 4100 g and 1120 g, respectively [17, 20]. The residence
time of the red marrow could therefore be calculated as 6.8% of
the blood residence time. In RIT with 131I-labelled MAbs, the
maximum amount of activity which can be administered safely is
assumed to be the activity dose that results in a 2-Gy dose to the
red marrow [11, 22]. The dose to all other tissues was calculated
using this maximum amount of activity. The absorbed dose to the
red marrow was estimated using the adult female phantom in the
MIRDOSE3 program [20].
Effective dose. &p.2:For the i.p. route of administration the effective
dose was calculated from the mean values of 24 normal organ ab-
sorbed doses according to the methods given in ICRP 60 [23]. The
contributions of both the activity in the peritoneal cavity and the
activity in “the total body minus the peritoneal cavity” to the or-
gan doses were included. For the i.v. route of administration the
effective dose was calculated using the MIRDOSE3 program.
Tumour dose. &p.2:Three different contributions to the absorbed dose
in the tumours were included: penetrating radiation due to activity
in the whole body, non-penetrating radiation due to activity in tu-
mour tissue as measured ex vivo and, for the i.p. route, the elec-
tron dose due to the peritoneal cavity wall.
Due to the similarity in location and size, the ovaries were se-
lected as the surrogate for the intraperitoneal tumours for dose es-
timates due to penetrating radiation. The total tumour absorbed
dose from penetrating radiation was calculated as the sum of the
dose from activity in the peritoneal cavity and the absorbed dose
from the activity outside the peritoneal cavity as calculated with
MIRDOSE3 [20].
The accumulated activity in the tumour was estimated from an
ROI around the tumour in the last imaging study before surgery,
using the partial background correction method as described pre-
viously [24]. This uptake was compared with the estimated activi-
ty as measured ex vivo. It was assumed that the amount of activity
in the tumour was acquired instantaneously and remained con-
stant. Because RIT will most likely be applied after debulking sur-
gery [12, 13], it is important to estimate whether residual small tu-
mour lesions can receive therapeutic doses. Therefore, for three
patients, the calculated activity in large tumours, expressed as %
ID/g, following i.p. administration of 131I-cMOv18-IgG, was as-
signed to tumours of 1 g. For the 1-g tumours, the absorbed dose
due to self-absorption of the non-penetrating β-radiation was cal-
culated as the product of the residence time and the S-factor for a
1-g sphere (being 2.95E-02 mGy/MBq·s for 131I [25]), using the
nodule module option of the MIRDOSE3 program [20].
The absorbed dose in 1-g tumours due to activity in the perito-
neal cavity fluid was calculated as if the tumours were localised
on the inner surface of the peritoneal cavity wall [12]. The perito-
neal cavity wall was used as the surrogate for the small tumours
for electron dose estimates due to activity in the peritoneal cavity
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fluid. The estimated dose in the tumours due to beta radiation
from activity in the peritoneal cavity was calculated by multiplica-
tion of the dose rate factors for various distances from the perito-
neal cavity into the cavity wall by the mean residence time of the
activity in the peritoneal cavity fluid. A volume-distributed source
in the peritoneal cavity was assumed, since prior to the i.p. admin-
istration of 131I-cMoV18 IgG, a volume of approximately 1.5 l of
saline was infused into the peritoneal cavity [19].
Results
Pharmacokinetics
The concentration of radioactivity in the blood (% ID/l)
was not affected by the administered protein dose; there-
fore, the blood clearance data from all patients of each
route of administration were pooled. The mean blood
time-activity curves are shown in Fig. 1. For the i.p.
route, the peak blood activity concentration was reached
between 48 and 96 h p.i and averaged 10%±2% ID/l.
Radioactivity in the blood was described by a bi-expo-
nential curve with a mean half-life of 6.9±3.2 h p.i. for
the accumulation phase and a mean half-life of 160±45 h
for the elimination phase. For i.v. infusion, the blood da-
ta were described by a bi-exponential curve with a bio-
logical half-life for the elimination phase of 103±12 h.
The peak blood concentration, 23%±6% ID/l, was
reached at 3.0±0.4 h p.i.
For both routes of administration the radioactivity ap-
peared in the urine gradually. Maximum excretion was
observed shortly after the maximum blood concentration
had occurred. At 96 h after injection, the mean cumula-
tive excretion of the radiolabel in the urine was 17%±3%
ID and 21%±7% ID for i.p. and i.v. administration, re-
spectively. For the i.v. route, the mean half-life for elimi-
nation of activity from the total body was 309 h, based
on the mean excretion of activity in the urine.
Fig. 1. Time-activity curves for the blood after i.p. (n=8) and
i.v. infusion (n=4) of 131I-cMOv18-IgG in patients suspected of
having ovarian cancer. Mean values ±SEM (% ID/l) &/fig.c:
%
 ID
/l
time p.i. (h)
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Radioimmunoscintigraphy
Eight patients were imaged after i.p. administration of
131I-cMOv18. Histological data of the tumours removed
at surgery are summarized in Table 1. Three patients had
an epithelial ovarian cancer (nos. 2, 9 and 10), two pa-
tients were diagnosed as having a non-ovarian malignan-
cy (nos. 3 and 5) and the remaining three patients had
benign gynaecological tumours.
Immediately after intraperitoneal activity infusion,
the estimated activity within the abdominal region was
only 80% of the activity in the total body ROI. This is
probably due to scattered radiation and penetration of
the high-energy photons through the lead septa of the
high-energy collimator. Therefore, the count rate in the
abdomen ROI at the first image was set equal to 100%
ID, while on subsequent images, the count rate within
the abdomen ROI was divided by a factor of 0.8 in order
to correct for scatter and collimator penetration.
In all patients, the radioimmunoconjugate diffused
throughout the peritoneal cavity as observed on the 1-h
p.i. images (Fig. 2). Up until 24 h p.i., the radioactivity
was confined to the peritoneal cavity. At later time
points the radioactivity appeared in the circulation. All
ovarian carcinoma lesions that were found at surgery
were visualised in the three patients having epithelial
ovarian cancer. A typical example of such an image is
shown in Fig. 3. None of the benign ovarian tumours
(n=3) showed elevated uptake. In addition, no elevated
uptake was seen in the patient with an endometrium cor-
pus carcinoma or the patient with a non-Hodgkin’s lym-
phoma. After the radioimmunoconjugate had reached its
maximum blood level, no retention of activity was seen
in normal organs such as liver, kidneys or bone marrow.
Tumour uptake
After i.p. administration the uptake in the tumour depos-
its in the three patients having malignant ovarian cancer,
as measured ex vivo, ranged from 3.4% to 12.3% ID/kg,
corresponding to a total uptake in the resected tumours
of 3.3%, 2.8% and 1.8% ID. From gamma camera imag-
es the uptake in these tumours was estimated as 3.0%,
3.1% and 2.6% ID. The uptake in benign tumours
ranged from 0.5% to 1.8% ID/kg. Uptake in non-ovarian
malignancies varied from 0.1% to 2.1% ID/kg. Mean up-
take in muscle tissue was 1.4%±0.5% ID/kg. The tu-
mour-to-muscle ratios ranged from 3 to 8 in patients
with malignant ovarian tumours, whereas in the patients
with benign tumours this ratio varied from 0.1 to 1.3. In
the patients with a non-ovarian malignancy the tumour-
to-muscle ratios ranged from 0.1 to 2.6.
For the i.v. route of administration the uptake in ma-
lignant ovarian tumour deposits ranged from 3.6% to
5.4% ID/kg. The tumour-to-non-tumour ratio ranged
from 1.3 to 2.7.
Fig. 2. Anterior planar image at 1 h p.i. showing the distribution
of the radio-immunoconjugate through the peritoneal cavity &/fig.c:
Fig. 3. Anterior planar image at 144 h p.i. of a patient with a
serous adenocarcinoma of both ovaries showing elevated tumour
uptake
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Organ doses
The retention of activity in total body, the abdomen and
the peritoneal cavity for the i.p. route of administration
are summarized in Table 3. Mean total body retention
was 63%±7% ID at 144 h p.i. The whole-body biologi-
cal half-life ranged from 104 to 590 h. The retention of
activity in the peritoneal cavity was 20%±4% ID after
144 h p.i. The residence times of the urinary bladder and
the “rest of the body” were 0.44±0.16 and 80±22 h, re-
spectively. The absorbed doses for the target organs
ranged from 0.35 mSv/MBq for the lungs to
1.59 mGy/MBq for the pancreas (Table 4). The contribu-
tion of the activity in the peritoneal cavity to the total
absorbed doses in the abdominal organs ranged from
39%–82% (Table 4). The absorbed dose to the target or-
gans after i.v. administration ranged from 0.40 mSv/
MBq for the skin to 0.57 mSv/MBq for the red marrow.
The absorbed dose to the lungs was 0.49 mSv/MBq.
Red marrow dose
The mean residence time for the red marrow based on
the pooled blood time-activity data was 3.05 h after i.p.
administration of 131I-cMOv18 IgG. The mean absorbed
dose in the red marrow was 0.49±0.04 mGy/MBq. The
contribution from the activity in the peritoneal cavity to
the total red marrow dose was 32% (Table 4). Assuming
that an absorbed dose of 2 Gy in the red marrow is the
maximum dose that will not induce grade 4 toxicity
(MTD), 4.1 GBq of 131I-cMOv18 IgG could be adminis-
tered safely.
For i.v. administration, the absorbed dose in the red
marrow based on the pooled blood time-activity data
was 0.57 mGy/MBq, and thus for this route of adminis-
tration a maximal tolerable dose of 3.5 GBq 131I-
cMOv18 IgG was estimated.
Effective dose
Following i.p. administration, the effective dose, based
on the mean organ doses, was 0.55 mSv/MBq, resulting
in an effective dose of 82 mSv for the 150 MBq 131I-
cMOv18 IgG administered in this study. For the i.v.
route of administration the effective dose was
Table 3. Retention in total body, abdomen and peritoneal cavity
based on ROI measurements after i.p. administration &/tbl.c:&tbl.b:
Time p.i. No. of Retentiona
(h) patients
Total body Abdomen Peritoneal cavity
1 8 100 100±0 99±2
24 7 94±4 86±10 80±13
48 6 91±6 60±11 50±13
72 5 84±4 45±5 35±3
120 7 71±10 33±5 24±6
144 6 63±7 29±3 20±4
a Expressed as percentage of the total body activity directly after
i.p. injection (% ID). Mean values ± s.d. &/tbl.b:
Table 4. Absorbed dose in target organs
from activity in the peritoneal cavity and in
the “total body minus peritoneal cavity” af-
ter i.p. administration &/tbl.c:&tbl.b:
Organ Dose due to Dose due to Total absorbed Peritoneal
activity in the activity in the dose contribution
peritoneal cavity “total body (mGy/MBq) (%)
(mGy/MBq) minus peritoneal
cavity”
(mGy/MBq)
Adrenals 0.45±0.06 0.28±0.07 0.73±0.08 62±7
Small intestine 0.54±0.07 0.32±0.11 0.85±0.1 64±9
Stomach 0.33±0.05 0.27±0.07 0.61±0.07 55±7
Colon 0.31±0.04 0.33±0.12 0.63±0.1 50±9
Kidneys 0.36±0.05 0.27±0.06 0.63±0.07 58±7
Liver 0.30±0.04 0.27±0.06 0.57±0.07 53±7
Lungs 0.09±0.01 0.26±0.05 0.35±0.05 26±5
Ovariesa 0.36±0.05 0.29±0.06 0.65±0.07 55±6
Pancreas 1.31±0.16 0.28±0.06 1.59±0.17 82±4
Red marrow 0.16±0.02 0.33±0.07 0.49±0.04 32±4
Bone surfaces 0.09±0.01 0.28±0.07 0.37±0.07 25±5
Spleen 0.20±0.03 0.27±0.06 0.46±0.06 43±7
Urinary bladder 0.23±0.03 0.38±0.11 0.61±0.10 39±9
a With respect to dosimetry, ovaries were used as the surrogate for tumours. Only absorbed
dose to the ovaries due to penetrating radiation is presented. The mean absorbed dose to
the ovaries is derived from the five patients having no malignant tumour. For all other or-
gans the contribution of activity in the tumour to the absorbed dose is included. The ab-
sorbed dose to these organs is averaged over eight patients &/tbl.b:
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0.52 mSv/MBq, resulting in an effective dose of 3.9 mSv
after administration of 7.5 MBq 131I-cMOv18 IgG.
Tumour dose
For the i.p. route of administration the tumour absorbed
dose due to penetrating radiation was 0.65±
0.07 mGy/MBq (Table 4). For i.v. administration the tu-
mour absorbed dose due to activity in the whole body
was 0.57 mSv/MBq. Thus, the additional dose to the tu-
mour due to penetrating radiation after i.p. administra-
tion of 4.1 GBq of 131I-cMOv18 will be 2.7 Gy, while
the additional dose to the tumour following i.v. adminis-
tration of 3.5 GBq of 131I-cMOv18 will be 1.9 Gy.
For i.p. administration, the residence time of the large
tumours, as measured ex vivo, ranged from 9.4 to
34.0 h/kg, and thus from 0.0094 to 0.034 h for 1-g tu-
mours. The absorbed doses to 1-g lesions due to non-
penetrating radiation ranged from 1.0 to 3.6 mGy/MBq.
For an administered activity of 4.1 GBq a maximum of
15 Gy could be delivered to these tumour lesions due to
self-absorption of the beta-radiation. For the i.v. route,
the residence time for large tumours ranged from 10 to
15 h/kg, based on an initial uptake varying from 3.6% to
5.4% ID/kg. The absorbed dose to the 1-g tumours
ranged from 1.1 to 1.6 mGy/MBq, due to self-absorp-
tion. Therefore, 3.5 GBq 131I-cMOv18 IgG administered
intravenously would result in a maximum absorbed dose
of 5.6 Gy to these tumours for self-absorption only.
The dose rate from electrons emitted by the activity
present in the peritoneal cavity surrounding the tumour
ranged from 3.0±0.4 mGy/MBq at the tumour surface to
1.0±0.1 mGy/MBq at a distance of 0.2 mm from perito-
neal cavity into the tumour. At a distance of 1 mm from
the peritoneal cavity into the tumour the dose rate was
less than 0.03 mGy/MBq (Table 5). For an administered
activity of 4.1 GBq 131I-cMOv18 IgG via the i.p. route,
the absorbed electron dose ranged from 12.3 Gy at the
tumour surface to 4.1 Gy at a distance of 0.2 mm from
the intraperitoneal cavity into the tumour.
The total dose to the tumour was calculated as the
sum of the dose from penetrating radiation and non-
penetrating radiation in the tumour due to self-absorp-
tion of the activity in the tumour itself. For the i.p. route
of administration the total dose ranged from 1.7 to
4.3 mGy/MBq. For the i.v. route of administration this
range was 1.7–2.2 mGy/MBq. At MTD (4.1 GBq i.p.) a
maximum dose of 18 Gy could be delivered to the tu-
mour. If the electron dose to the tumour from peritoneal
activity is also taken into account, a total absorbed dose
of 30 Gy can be reached at the tumour surface and a
dose of 22 Gy at 0.2 mm depth.
For the i.v. route of administration a maximum ab-
sorbed dose of 8 Gy could be delivered to the tumour af-
ter injection of 3.5 GBq 131I-cMOv18 IgG.
Discussion
The aim of the present study was to investigate the do-
simetry associated with the i.p. and i.v. administration of
radioiodinated cMOv18 IgG in ovarian cancer patients.
Pharmacokinetics and biodistribution
Planar images showed good distribution throughout the
peritoneal cavity in all patients following i.p. administra-
tion of 131I-cMOv18 IgG.
The mean whole-body retention measured 84% and
80% ID at 96 h p.i. after i.p. and i.v. injection, respec-
tively. Crippa et al. reported a much faster whole-body
excretion of the murine MOv18 MAb after i.p. adminis-
tration: 20% ID was present in the total body at 96 h p.i.
[1]. Crippa et al. used a 1-mg protein dose, while in the
present study 15–80 mg was administered. This suggests
that at very low protein doses the whole-body clearance
Table 5. Electron doses in the tumour wall
from volume distributed sources of 131I af-
ter i.p. administration &/tbl.c:&tbl.b:
Distance from Volume source Dose rate for Absorbed dose
peritoneal cavity electron dose volume 1500 gb for 4.1 GBq
into peritonial (mGy-g/MBq-sec) (mGy/MBq) (Gy)
cavity walla
(cm)
0.000 0.015 3.00 12.3
0.001 0.014 2.80 11.4
0.003 0.011 2.20 9.0
0.006 0.009 1.80 7.4
0.018 0.005 1.00 4.1
0.030 0.0028 0.56 2.3
0.050 0.00105 0.21 0.86
0.080 0.00015 0.03 0.12
a Data in columns 1 and 2 were derived from Watson et al. [19]
b For each distance, data in column 3 were calculated using the formula: (data column 2) ×
(mean residence time for peritoneal cavity: 83.3 h) × (3600 [s/h])/(1500 [g]) &/tbl.b:
may be enhanced. We have observed this same phenom-
enon with the cG250 antibody. This antibody also
cleared faster when 2 mg was administered as a protein
dose as compared to doses ≥5 mg [26]. Immunohistolog-
ical studies in experimental tumour models have shown
that higher protein doses of antibody may enhance the
tumour penetration. Therefore, unless antigen saturation
occurs, high protein doses may be more optimal for RIT
[12].
Tumour uptake. &p.1:Comparison of tumour uptake derived
from gamma camera images and uptake determined ex
vivo after i.p. administration showed an excellent corre-
lation: in three patients an uptake of 3.0%, 3.1% and
2.6% ID was derived from gamma camera ROIs, while
the ex-vivo measurements of these tumours indicated an
uptake of 3.3%, 2.8% and 1.8% ID, respectively.
Tumour dosimetry. &p.1:After completing the course of che-
motherapy, ovarian cancer patients may undergo second-
look laparotomy (SLL) to assess their disease status.
Persistent disease diagnosed by SLL has been observed
in 45%–80% of patients with advanced disease [27].
However, negative findings at SLL are not a definitive
sign of tumour eradication. Within 5 years, 24% of the
patients with a negative SLL presented recurrent disease
[28]. In these situations small tumours or metastases
may be present in the peritoneal cavity, on the peritoneal
cavity wall or in the small intestine. Therefore, for the
i.p. route of administration, special attention was given
to estimate the absorbed dose to small tumours [12, 13].
The absorbed dose estimations were based on the as-
sumptions that the tumour uptake level and the tumour
residence time per gram tissue in small tumour deposits
will be the same as in large tumours. This is a conserva-
tive approximation: several studies have shown that anti-
body uptake is higher in small tumours [12, 13, 29].
Comparing tumours of different sizes (e.g. 1–1000 g),
but with equal uptake of activity (131I) per gram, the
dose to small tumours will be 25% lower than that to
large tumours, due to a higher self-absorption of photon
energy in the large tumours [25]. Moreover, in microme-
tastases with clusters of tumour cells (10 µm radius
spheres) part of the beta-energy from activity in the tu-
mour will not be absorbed in the small spheres, resulting
in lower doses, depending on the radionuclide used [12,
25]. However, cross-radiation from the beta-radiation
emitted by the activity in the peritoneal cavity after i.p.
administration of 131I-cMOv18 IgG may increase the ab-
sorbed dose in these small tumours.
In the present study, the absorbed dose in the tumours
varied from 1.7 to 4.3 and 1.7 to 2.2 mGy/MBq after i.p.
and i.v. administration, respectively. This is in the same
range as was reported by Behr et al (2–4 mGy/MBq) af-
ter i.v. administration of 131I-labelled IgG anti-CEA anti-
bodies in CEA-expressing cancers [10]. For the i.p. route
of administration the tumour dose may be enhanced with
3 mGy/MBq at the tumour surface and 1 mGy/MBq at
0.2 mm depth in the tumours, due to the electron dose
from activity in the peritoneal cavity [19]. Thus, includ-
ing the electron dose due to activity in the peritoneal
cavity in the dose estimates, absorbed doses of 30 and
22 Gy can be reached at the tumour surface and at
0.2 mm depth in the tumour, respectively.
Intraperitoneal versus intravenous administration
The area under the blood time-activity curve from time
of administration to time of surgery (AUC, biological)
was estimated as 10 and 21 h/l for the i.p. route and the
i.v. route, respectively. If MAb blood level were the driv-
ing force for antibody accumulation in tumours, the tu-
mour uptake would be expected to be at least as high or
even a factor of 2 higher after i.v. administration than af-
ter i.p. administration. However, such a relation was not
found in our study: the uptake in ovarian carcinoma tu-
mours, measured ex vivo, ranged from 3.4% to 12.3%
ID/kg and from 3.6% to 5.4% ID/kg for the i.p. and i.v.
routes of administration, respectively. The tumour up-
take data in the current study are in accordance with
findings of previous clinical studies reporting higher tu-
mour uptake after i.p. administration as compared to i.v.
injection [1, 9]. Crippa et al. [1] also found a more fa-
vourable biodistribution after i.p. administration of mu-
rine 131I MOv18 than after i.v. administration. These da-
ta suggest that possibly direct tumour uptake after i.p.
administration (non-systemic supply) causes the major
part of the uptake of the antibody in the tumour. Another
main advantage of locoregional administration is the re-
duced uptake in normal tissues, e.g. lungs and red mar-
row. In this study, the mean estimated radiation doses to
the lungs were 0.35 and 0.49 mGy/MBq after i.p. admin-
istration and i.v. administration, respectively. For the red
marrow the absorbed doses were 0.49 and
0.57 mGy/MBq, respectively. In addition, in the case of
RIT the relatively long retention in the peritoneal cavity
may result in an increased absorbed dose to small tu-
mour nodules on the peritoneal wall and on the intestine
due to the prolonged bathing in a radiolabelled MAb flu-
id.
In general, the accuracy of tumour dose calculations
is limited due to factors such as assumption of uniform
distribution of activity throughout a tumour and the inac-
curate assumption of initial uptake [30]. In the current
study it was assumed that the activity in the tumour,
found at surgery, was instantaneously present at the time
of administration [31]. Only physical decay was consid-
ered. For the i.p. route of administration the count rate in
the tumour ROI on the gamma camera images increased
during the first 24–48 h after injection and was stable on
later images. Thus, the assumption of initial uptake in
the tumour may have led to a minor overestimation of
the absorbed dose. Such an overestimation may be coun-
teracted by a likely increase of activity in the period af-
ter 7 days p.i. if no surgery would be performed.
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In summary, the data from this study suggest that the
i.p. route of administration is preferable to the i.v. route.
Use of tracer dose images to predict therapy doses
Tumour uptake and, consequently, the radiation dose to
the tumour seem to vary considerably between patients
[10, 11, 31]. Based on the dosimetric analysis of the data
obtained after i.p. injection of 131I-labelled B72.3 IgG in
ten patients with adenocarcinoma, Larson et al. recom-
mended that the radiation dose should be estimated on
an individual basis using a diagnostic dose in order to
determine the efficacy of a therapeutic dose [31]. Other
authors have confirmed the necessity of this approach
[32–35]. Haematopoietic toxicity is usually the dose-
limiting factor in RIT [21, 31, 35, 36]. For bone marrow,
2 Gy is considered to be the maximum tolerated dose
[31]. Our calculations indicate that the radiation dose to
the marrow will amount to an MTD of 2 Gy, after ad-
ministration of 4.1 or 3.5 GBq for i.p. and i.v. adminis-
tration, respectively. Extrapolating the dosimetric data of
the tumours measured ex vivo in the current study, the
maximum radiation dose to 1-g tumour deposits was es-
timated to be 18 Gy at a 4.1 GBq dose for the i.p. route
and 8 Gy at a 3.5 GBq dose for the i.v. route of adminis-
tration. After i.p. administration of 4.1 GBq, an addition-
al dose of 12 and 4 Gy can be absorbed at the tumour
surface and at a depth of 0.2 mm, respectively.
An absorbed dose of 20 Gy is considered a tumour-
sterilising level for tumours with a diameter of 0.3 mm
[12], and thus 131I-cMov18-IgG could potentially induce
therapeutic response, especially upon i.p. administra-
tion.
In clinical patient management it is usually impracti-
cal to collect data for blood, urine and tissue uptake for
more than a few days. The calculation of the residence
times in the organs or tumours was therefore based on
the limited data for uptake of activity in the organs dur-
ing the sampling period, which will result in inaccurate
estimates of the absorbed dose. If the sampling period is
less than or equal to the effective half-time of the radio-
pharmaceutical, the error in the estimated dose may ex-
ceed 100%. To reduce these errors, application of physi-
cal, biological or mathematical models for the time-
activity curves [37, 38] and use of special computer
programs [39] may be helpful, permitting more accu-
rate determination of the residence times and absorbed
doses.
In conclusion, the concept of targeting radiolabelled
antibodies towards tumour cells remains an attractive
therapy concept for ovarian cancer patients. The i.p.
route of administration seems to be preferable to i.v. ad-
ministration: tumour uptake is at least as high after i.p.
administration while haematopoietic toxicity is reduced.
Chimeric MOv18 IgG seems to offer a therapeutic ad-
vantage particularly in patients with small tumour depos-
its.
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